DrugPatentWatch Database Preview

Details for Patent: 9,045,519

« Back to Dashboard

Which drugs does patent 9,045,519 protect, and when does it expire?

Patent 9,045,519 protects LEXISCAN and is included in one NDA.

This patent has twenty-nine patent family members in twenty-three countries.

Summary for Patent: 9,045,519

Title:	N-pyrazole A.sub.2A receptor agonists
Abstract:	The present disclosure provides a process for the preparation of 2-adenosine N-pyrazole compounds exemplified by the structure shown below that are potent and selective agonists for A.sub.2A adenosine receptor, compositions comprising these compounds, and methods for using these compound to stimulate mammalian coronary vasodilatation for imaging the heart. ##STR00001##
Inventor(s):	Zablocki; Jeff A. (Mountain View, CA), Elzein; Elfatih O. (Fremont, CA), Palle; Venkata P. (Pune, IN), Belardinelli; Luiz (Palo Alto, CA)
Assignee:	Gilead Sciences, Inc. (Foster City, CA)
Application Number:	14/020,736
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 9,045,519

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astellas	LEXISCAN	regadenoson	SOLUTION;INTRAVENOUS	022161-001	Apr 10, 2008		RX	Yes	Yes			Y

International Family Members for US Patent 9,045,519

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	024441
Austria	256141
Australia	7132400
Australia	760806
Brazil	0011856
Canada	2377746